Advertisement
HRTX vs SION
Which Stock Would AI Choose? Heron Therapeutics (HRTX) vs. Sionna Therapeutics (SION) Stock Comparison
Key Takeaways
- Both HRTX and SION have experienced severe price declines in 2026, though for fundamentally different reasons: patent risk versus a failed clinical trial.
- Heron Therapeutics is a commercial-stage biotech with recurring product revenue, while Sionna Therapeutics is pre-revenue and depends entirely on its cystic fibrosis pipeline.
- Heron's setback stems from an adverse CINVANTI patent ruling and withdrawn guidance; Sionna's stems from the Phase 2a failure of lead candidate SION-719.
- Sionna retains a substantially larger cash cushion (roughly $268 million as of mid-2026) than Heron's balance sheet, but faces binary clinical risk ahead.
- Both names carry elevated volatility and speculative profiles, making them most relevant to traders comfortable with high-risk, event-driven biotechnology exposure.
- For more detail on each company's developments, explore the HRTX Major News and HRTX Today's Price Move pages, as well as SION Major News and SION Today's Price Move.
- To see how automated strategies are positioning across these and other tickers, explore Trending AI Robots.
Introduction
This stock comparison examines two biotechnology companies navigating very different stages of the corporate lifecycle. HRTX (Heron Therapeutics) is a commercial-stage acute-care and oncology drugmaker generating real revenue but contending with legal and competitive pressures. SION (Sionna Therapeutics) is a clinical-stage cystic fibrosis developer with no product sales and a pipeline reset after a pivotal trial miss. Both have suffered steep drawdowns recently, making their relative performance, market positioning, and risk profiles a useful case study for traders weighing distressed and speculative biotech opportunities.
HRTX Overview and Recent Performance
Heron Therapeutics develops and commercializes acute-care and oncology supportive-care products, including ZYNRELEF (a non-opioid postsurgical pain treatment), APONVIE (for postoperative nausea and vomiting), CINVANTI, and SUSTOL. In recent weeks the company reported quarterly net product sales in the mid-$30 million range, with its acute-care franchise growing year over year even as legacy oncology products declined.
Sentiment deteriorated sharply following an adverse patent ruling related to CINVANTI, which raised the prospect of generic competition. In response, management withdrew its full-year financial guidance, tightened spending, and indicated it is evaluating strategic alternatives. Analysts downgraded the stock, and the share price has fallen substantially year to date to a low single-digit fraction of a dollar, leaving a micro-cap valuation. The central debate for investors is whether ZYNRELEF and APONVIE growth can offset CINVANTI erosion while the company manages a constrained balance sheet.
SION Overview and Recent Performance
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF), developing NBD1 (nucleotide-binding domain 1) stabilizers designed to target the underlying F508del mutation in the CFTR protein. The company completed its initial public offering (IPO) in early 2025 and has no approved products or revenue.
Recent market activity has been dominated by the failure of lead candidate SION-719 in its Phase 2a proof-of-concept trial as an add-on to standard-of-care therapy. The trial missed its key endpoint, showing no statistically significant reduction in sweat chloride, and the company discontinued that development path. The shares fell roughly 90% in response, and Sionna subsequently announced a workforce reduction of about 46% to extend its cash runway into the second half of 2029. Attention has shifted to the earlier-stage SION-451 and SION-2222 combination, with a Phase 2a study anticipated in early 2027.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading strategies drawn from a much larger universe. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each built around distinct trading styles, strategies, timeframes, and performance statistics such as win rate, trade frequency, and drawdown. Because not every bot suits every market regime, only those deemed most appropriate for current conditions earn placement in this featured section. This makes the page a useful starting point for traders seeking to understand how algorithmic strategies are adapting to shifting volatility and momentum. Explore the Trending AI Robots page to review the currently featured bots.
Head-to-Head Comparison
The two companies differ most fundamentally on stage and business model. HRTX is a commercial-stage operator with an established sales infrastructure and multiple marketed products, giving it recurring revenue but also pricing and competitive exposure. SION is pre-revenue, so its value rests almost entirely on future clinical milestones and intellectual property.
On growth drivers, Heron's near-term story hinges on reimbursement expansion and adoption of ZYNRELEF and APONVIE, while Sionna's depends on validating its remaining combination therapy. Risk factors also diverge: Heron faces patent, generic-competition, and balance-sheet risks, whereas Sionna faces binary trial risk and future dilution. In terms of market sentiment, both have been de-rated aggressively, though Sionna retains a larger cash reserve that may cushion operational runway. Sector exposure overlaps in biotechnology, but the companies serve different therapeutic and commercial niches.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view neither name as a high-conviction trend candidate, given the absence of sustained positive momentum in either chart. Between the two, relative positioning may tilt slightly toward HRTX on the basis of recurring revenue, an existing commercial infrastructure, and a more diversified product base, which together offer more quantifiable near-term catalysts than a pre-revenue pipeline. However, Heron's constrained liquidity and legal overhang temper that view. Sionna's cleaner balance sheet and long runway are notable strengths, but its dependence on a single early-stage program introduces greater uncertainty. The verdict is therefore probabilistic rather than definitive: whichever stock demonstrates clearer trend consistency and a concrete catalyst is most likely to attract algorithmic attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRTX is a Hold and SION is a Hold.
Momentum Indicator for HRTX turns negative, indicating new downward trend
HRTX saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 73 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HRTX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
HRTX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
HRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 141 cases where HRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SION in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
SION may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 9 of 10 cases where SION's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where SION advanced for three days, in 99 of 115 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SION declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for SION entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.558) is normal, around the industry mean (3.498). P/E Ratio (-1.526) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SION’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SION’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HRTX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 89 | |
P/E GROWTH RATING 1..100 | 13 | |
SEASONALITY SCORE 1..100 | 26 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| HRTX | SION | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 78% |
| Stochastic ODDS (%) | 4 days ago 83% | 4 days ago 89% |
| Momentum ODDS (%) | 4 days ago 90% | N/A |
| MACD ODDS (%) | 4 days ago 82% | N/A |
| TrendWeek ODDS (%) | 4 days ago 83% | 4 days ago 83% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 81% |
| Advances ODDS (%) | 13 days ago 84% | 13 days ago 86% |
| Declines ODDS (%) | 11 days ago 89% | 7 days ago 84% |
| BollingerBands ODDS (%) | 4 days ago 80% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 77% | 4 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HRTX’s FA Score shows that 1 FA rating(s) are green while SION’s FA Score has 2 green FA rating(s).
- HRTX’s FA Score: 1 green, 4 red.
- SION’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HRTX’s TA Score shows that 4 TA indicator(s) are bullish while SION’s TA Score has 4 bullish TA indicator(s).
- HRTX’s TA Score: 4 bullish, 5 bearish.
- SION’s TA Score: 4 bullish, 2 bearish.
Price Growth
HRTX (@Biotechnology) experienced а +5.51% price change this week, while SION (@Biotechnology) price change was -15.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
HRTX is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
HRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with FULC. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To HRTX | 1D Price Change % | ||
|---|---|---|---|---|
| HRTX | 100% | +4.64% | ||
| FULC - HRTX | 49% Loosely correlated | +0.54% | ||
| ABVX - HRTX | 45% Loosely correlated | +1.85% | ||
| AMRN - HRTX | 44% Loosely correlated | +0.30% | ||
| SION - HRTX | 41% Loosely correlated | N/A | ||
| TENX - HRTX | 40% Loosely correlated | +3.68% | ||
More | ||||
SION and
Correlation & Price change
A.I.dvisor indicates that over the last year, SION has been closely correlated with TENX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if SION jumps, then TENX could also see price increases.
| Ticker / NAME | Correlation To SION | 1D Price Change % | ||
|---|---|---|---|---|
| SION | 100% | N/A | ||
| TENX - SION | 93% Closely correlated | +3.68% | ||
| PLRX - SION | 43% Loosely correlated | -0.75% | ||
| MGTX - SION | 42% Loosely correlated | +5.76% | ||
| HRTX - SION | 41% Loosely correlated | +4.64% | ||
| BCAX - SION | 40% Loosely correlated | +5.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NBFR | 24.82 | 0.30 | +1.21% |
| Innovator Nasdaq-100 Managed 10 Buffer ETF (NBFR) | |||
| FLRG | 40.51 | N/A | N/A |
| Fidelity U.S. Multifactor ETF (FLRG) | |||
| EMO | 48.00 | -0.11 | -0.23% |
| ClearBridge Energy Midstream Opportunity Fund | |||
| NXPG | 8.11 | -0.03 | -0.37% |
| Leverage Shares 2X Long NXPI Daily ETF (NXPG) | |||
| XUDV | 32.53 | -0.40 | -1.22% |
| Franklin U.S. Dividend Mltplr Idx ETF | |||